By Andrea Anderson

SAN DIEGO (GenomeWeb News) – While genome-wide association studies have long been considered an avenue for improving diagnostics, prognostics, and treatment, their most immediate application appears to be for improving drug safety and decreasing adverse events, according to Lon Cardon, senior vice president of GlaxoSmithKline's genetics program.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.